News
Day 3 - Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Year of the Wolf: Lupus at EULAR2020
For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf. Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress confer
Serum calprotectin: a better biomarker in ANCA-associated vasculitis?
Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.
Day 2 – Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020.
Are we doing our best treating seronegative arthritides?
Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis.
RheumNow Podcast – The Future of JAKs (6.5.20)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
EULAR and ACR COVID19 Guidelines: Similarities Provide Reassurance
In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.
Preventing COVID - Masks, Meters and Eyewear
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19. The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
Hydroxychloroquine Postexposure Prophylaxis for COVID-19 Fails
NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.
Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.
TNR Grand Rounds - Update on Biosimilars
This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
